… , probing the existing antiviral and other drugs against SARS-CoV2 is cost-effective. In recent
times, repurposing of available drugs for the management of several disease conditions is …

… to years to develop new drug/vaccine … drug repurposing techniques and the ability to
repurpose current therapeutic agents for COVID-19 treatment. Drug repurposing (reprofiling, drug …

… drug discovery against this disease. We explore the prevalence of this confound in SARS-CoV-2
repurposing … hits rapidly so as to focus on drugs with genuine potential against COVID-…

… drugs that specifically target SARS-CoV-2. Until an effective vaccine is available, repurposing
FDA approved drugs … reduce the cost compared to de novo drug discovery. In this study we …

… of the related human virus SARS-CoV, and the two … SARS-CoV-2 infection [[14]]. The
resulting gap in knowledge forms a major obstacle on the road towards effective drug repurposing …

… that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are …
how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 …

… to de novo drug discovery. In this study, we present an integrative, antiviral drug
repurposing … between the HCoV–host interactome and drug targets in the human protein–protein …

… SARS-CoV-2 … SARS-CoV-2 host interactome exploration and drug (target) identification.
CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-…

… against SARS-CoV-2. From a library of 1,425 US Food and Drug Administration (FDA)-approved
compounds and clinical candidates, we identified 17 hits that inhibited SARS-CoV-2 …

… 53 approved drugs with anti-SARS-CoV-2 … drugs and 49 investigational drugs with anti-SARS-CoV-2
activity that can be considered for design of new clinical trials, especially drug …